Boon-Cher Goh, MD, on Cancer Drugs in Singapore: 3As (Availability, Accessibility, and Affordability)

First International Summit on Interventional Pharmacoeconomics

Deborah Collyar: What's In It for Patients?

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Deborah Schrag, MD, MPH, of Dana-Farber Cancer Institute, offers her perspective on near-equivalence, Bayesian noninferiority, and the value of cancer drug optimization.

Varsha Gandhi, PhD, on Ibrutinib

David A. Hyman, MD, JD, on Inclusive Shared Savings

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

May

Today In Oncology

Boon-Cher Goh, MD, on Cancer Drugs in Singapore: 3As (Availability, Accessibility, and Affordability)

Related Videos

Deborah Collyar: What's In It for Patients?

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Varsha Gandhi, PhD, on Ibrutinib

David A. Hyman, MD, JD, on Inclusive Shared Savings

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

FDA Approves Atezolizumab for Adjuvant Treatment of MRD-Positive MIBC

Sigmoidoscopy Reduces CRC Incidence Rates in Men in Norwegian Screening Study

Early Ovarian Cancer Minimally Invasive Surgery, Intraoperative Capsule Rupture, and Survival

Local Salvage Therapy for Post-Radiotherapy Local Recurrence of Prostate Cancer

Study Finds DLBCL Subtype May Have Higher Mortality Risk in Female Patients